Abstract

Dalteparin sodium in the management of thromboembolic disorders

Author(s): Agnes YY Lee

Low molecular weight heparins have largely replaced unfractionated heparin for the prevention and treatment of venous and arterial thromboembolic disease since they are efficacious, safe and more convenient. Dalteparin sodium (Fragmin^®, Pfizer Inc.) is a low molecular weight heparin produced by controlled nitrous acid depolymerization of unfractionated heparin. Although specific indications and usage vary across countries, dalteparin has received regulatory approval for use in preventing venous thromboembolism following major abdominal and orthopedic surgery, treating acute deep vein thrombosis, and preventing recurrent venous thromboembolism in cancer patients. It is also used for the treatment of unstable coronary arterial disease and prevention of clotting of the extracorporeal system during hemodialysis. More recent research efforts have examined the potential role of dalteparin as an antineoplastic agent. Dalteparin has significantly improved and simplified the management of venous thromboembolism and will remain a very useful anticoagulant of choice, particularly in the oncology population.